Bone and joint tissue penetration of the staphylococcusselective antibiotic afabicin in patients undergoing elective hip replacement surgery

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 3, 2019, Pages

  Menetrey, Annick ^a   Janin, Annick ^a   Pullman, John ^b   Scott Overcash, J ^c   Haouala, Amina ^a   Leylavergne, François ^a   Turbe, Laurent ^d   Wittke, Frederick ^a,e   Nicolas Métral, Valérie ^a  

^a DEBIOPHARM SA   (Switzerland)

^b St James Healthcare   (United States)

^c SHARP GROSSMONT HOSPITAL   (United States)

^d SOLVO BIOTECHNOLOGY   (Hungary)

^e MSD International   (Switzerland)

Author keywords

Afabicin; Debio 1450; Drug development; Drug penetration; Joint infections; Osteomyelitis; Pharmacokinetics; Staphylococcus aureus

Indexed keywords

AFABICIN; ANTIINFECTIVE AGENT; API 1252; BENZOFURAN DERIVATIVE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); PYRONE DERIVATIVE;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE RATIO; ARTICLE; BONE AND JOINT INFECTIONS; BONE MARROW; BONE TISSUE; CLINICAL ARTICLE; CORTICAL BONE; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG SYNOVIAL FLUID LEVEL; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ELECTIVE SURGERY; FEMALE; HIP REPLACEMENT; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MINIMUM INHIBITORY CONCENTRATION; MUSCLE SPASM; PARALYTIC ILEUS; PNEUMONIA; PRESYNCOPE; PRIORITY JOURNAL; SOFT TISSUE; STAPHYLOCOCCUS INFECTION; TRABECULAR BONE; VOMITING; BONE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; OSTEOMYELITIS; PHASE 1 CLINICAL TRIAL;

ANTI-BACTERIAL AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; BENZOFURANS; BONE AND BONES; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OSTEOMYELITIS; PROSTHESIS-RELATED INFECTIONS; PYRONES; STAPHYLOCOCCAL INFECTIONS;

EID: 85062267865     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01669-18     Document Type: Article

References (33)

1. Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Soergel F. 2009. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 48:89–124. https://doi.org/10.2165/00003088-200948020-00002.
2. Sheehy SH, Atkins BA, Bejon P, Byren I, Wyllie D, Athanasou NA, Berendt AR, McNally MA. 2010. The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti-microbial regimens. J Infect 60:338–343. https://doi.org/10.1016/j.jinf.2010.03.006.
3. Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ, Huddleston PM. 2015. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Joint Surg Am 97: 837–845. https://doi.org/10.2106/JBJS.N.01350.
4. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603–661. https://doi.org/10.1128/CMR.00134-14.
5. Tande AJ, Patel R. 2014. Prosthetic joint infection. Clin Microbiol Rev 27:302–345. https://doi.org/10.1128/CMR.00111-13.
6. Sana TG, Monack DM. 2016. Microbiology: the dark side of antibiotics. Nature 534:624–625. https://doi.org/10.1038/nature18449.
7. Pavia AT, Shipman LD, Wells JG, Puhr ND, Smith JD, McKinley TW, Tauxe RV. 1990. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella. J Infect Dis 161:255–260. https://doi.org/10.1093/infdis/161.2.255.
8. Kelly CP, Pothoulakis C, LaMont JT. 1994. Clostridium difficile colitis. N Engl J Med 330:257–262. https://doi.org/10.1056/NEJM199401273300406.
9. Mathews CJ, Weston VC, Jones A, Field M, Coakley G. 2010. Bacterial septic arthritis in adults. Lancet 375:846–855. https://doi.org/10.1016/S0140-6736(09)61595-6.
10. Hawser S, Gueny M, Rochat I, Morrissey I, Magnet S, Dieppois G. 2018. Activity of Debio 1452 against Staphylococcus spp. collected in 2015/ 2016, abstr P1824. Abstr 28th Eur Congr Clin Microbiol Infect Dis.
11. Barbier M, Menetrey A, Haouala A, Dieppois G, Wittke F, Vuagniaux G. 2016. Efficacy of the FabI inhibitor Debio 1450 for the treatment of Staphylococcus aureus-induced osteomyelitis in an experimental rat model, abstr O496. Abstr 26th Eur Congr Clin Microbiol Infect Dis.
12. Barbier M, Menetrey A, Haouala A, Bravo J, Wittke F, Jacqueline C, Vuagniaux G. 2016. Efficacy of the FabI inhibitor afabicin for the treatment of Staphylococcus aureus-induced acute osteomyelitis in rabbit, abstr 4495. Abstr ASM Microbe, Boston, MA. American Society for Microbiology, Washington, DC.
13. Dyon-Tafani V, Dieppois G, Cara A, Monteix A, Valour F, Josse J, Ferry T, Laurent F. 2018. Activity of Debio 1452 on intracellular Staphylococcus aureus in osteoblasts in vitro, abstr 5462. Abstr ASM Microbe, Atlanta, GA. American Society for Microbiology, Washington, DC.
14. Nowakowska J, Kuehn J, Vincent C, Wittke FL, Fresne-Languille S, Carton T, Leuillet S, Le Vacon F, Vuagniaux G. 2018. Staphylococcal-selective antibiotic preserves the human gut microbiota, abstr 2471. Abstr 28th Eur Congr Clin Microbiol Infect Dis.
15. Fluhler E, Vazvaei F, Singhal P, Vinck P, Li W, Bhatt J, de Boer T, Chaudhary A, Tangiuchi M, Rezende V, Zhong D. 2014. Repeat analysis and incurred sample reanalysis: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J 16:1167–1174. https://doi.org/10.1208/s12248-014-9644-1.
16. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–e55. https://doi.org/10.1093/cid/ciq146.
17. Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM, Petermann GW, Osmon DR. 2015. Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 61:e26–e46. https://doi.org/10.1093/cid/civ482.
18. Fetterly GL, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP. 2005. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 49:148–152. https://doi.org/10.1128/AAC.49.1.148-152.2005.
19. Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, Nicolau DP. 2005. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 49:1629–1632. https://doi.org/10.1128/AAC.49.4.1629-1632.2005.
20. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. 1988. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 32:1320–1322. https://doi.org/10.1128/AAC.32.9.1320.
21. Roy ME, Peppers MP, Whiteside LA, LaZear RM. 2014. Vancomycin concentration in synovial fluid: direct injection into the knee vs. intravenous infusion. J Arthroplasty 29:564–568. https://doi.org/10.1016/j.arth.2013.08.017.
22. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. 2002. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 50:747–750. https://doi.org/10.1093/jac/dkf207.
23. Boselli E, Breilh D, Djabarouti S, Bel JC, Saux MC, Allaouchiche B. 2007. Diffusion of ertapenem into bone and synovial tissues. J Antimicrob Chemother 6:893–896. https://doi.org/10.1093/jac/dkm296.
24. Montange D, Berthier F, Leclerc G, Serre A, Jeunet L, Berard M, Muret P, Vettoretti L, Leroy J, Hoen B, Chirouze C. 2014. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother 58:3991–3996. https://doi.org/10.1128/AAC.02344-14.
25. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldas-sarre J. 2015. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother 59: 1849–1855. https://doi.org/10.1128/AAC.04550-14.
26. Landersdoerfer CB, Kinzig M, Bulitta JB. 2009. Bone penetration of amoxicillin and clavulanic acid evaluation by population pharmacokinetics and Monte-Carlo simulation. Antimicrob Agents Chemother 53: 2569–2578. https://doi.org/10.1128/AAC.01119-08.
27. Stolle LB, Plock N, Joukhadar C, Arpi M, Emmertsen KJ, Buerger C, Riegels-Nielsen P, Kloft C. 2008. Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis. Scand J Infect Dis 40:24–29. https://doi.org/10.1080/00365540701509873.
28. Housman ST, Bhalodi AA, Shepard A, Nugent J, Nicolau DP. 2015. Vancomycin tissue pharmacokinetics in patients with lower-limb infections via in vivo microdialysis. J Am Podiatr Med Assoc 105:381–388. https://doi.org/10.7547/14-033.
29. Traunmuller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, Konz KH, Scharnagl E, Joukhadar C. 2010. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 65:1252–1257. https://doi.org/10.1093/jac/dkq109.
30. Traunmuller F, Schintler MV, Spendel S, Popovic M, Mauric O, Scharnagl E, Joukhadar C. 2010. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents 36:84 – 86. https://doi.org/10.1016/j.ijantimicag.2010.03.007.
31. Bader JC, Lakota EA, Bravo J, Dieppois G, Nicolas-Métral V, Miesel L, Lin KY, Ambrose PG, Bhavnani SM. 2017. Pharmacokinetic-pharmacodynamic analyses for Debio 1450 (afabicin), a staphylococcal-specific antibiotic, using data from a murine-thigh infection model, abstr 2176. Abstr ASM Microbe, New Orleans, LA. American Society for Microbiology, Washington, DC.
32. EMA. 2011. Guideline on bioanalytical method validation. EMEA/CHMP/ EWP/192217/2009, revision 1, corrections 2. EMA, London, United Kingdom.
33. Singh JK, Solanki A, Maniyar RC, Banerjee D, Shirsath VS. 2006. Rapid equilibrium dialysis (RED): an in-vitro high-throughput screening technique for plasma protein binding using human and rat plasma. J Chro-matogr A 1102:125–134. https://doi.org/10.4172/jbb.S14-005.